SQZ Biotechnologies Operating Margin 2020-2023 | SQZ
Current and historical operating margin for SQZ Biotechnologies (SQZ) over the last 10 years. The current operating profit margin for SQZ Biotechnologies as of March 31, 2023 is -369.96%.
| SQZ Biotechnologies Operating Margin Historical Data |
| Date |
TTM Revenue |
TTM Operating Income |
Operating Margin |
| 2022-12-31 |
$0.02B |
$-0.08B |
-385.71% |
| 2022-09-30 |
$0.02B |
$-0.08B |
-376.19% |
| 2022-06-30 |
$0.02B |
$-0.08B |
-339.13% |
| 2022-03-31 |
$0.03B |
$-0.07B |
-296.00% |
| 2021-12-31 |
$0.03B |
$-0.07B |
-251.85% |
| 2021-09-30 |
$0.02B |
$-0.07B |
-435.29% |
| 2021-06-30 |
$0.02B |
$-0.06B |
-355.56% |
| 2021-03-31 |
$0.02B |
$-0.06B |
-289.47% |
| 2020-12-31 |
$0.02B |
$-0.05B |
-255.00% |
| 2020-06-30 |
$0.02B |
$-0.03B |
-181.25% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.018B |
$0.021B |
|
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
|
